On February 26, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. received a “Notice of Acceptance” for the registration and marketing license application for mesalazine enteric tablets issued by the State Drug Administration.
Mesalazine is a non-steroidal anti-inflammatory drug that can inhibit the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediators leukotriene, thereby significantly inhibiting inflammation of the intestinal mucosa. The product applying for marketing approval is mesalazine enteric tablets, which release mesalazine in the intestines after oral administration. They are suitable for the treatment of acute episodes of ulcerative colitis, maintenance treatment to prevent recurrence, and treatment during acute episodes of Crohn's disease. It was originally developed by German Fokker Pharmaceuticals Co., Ltd. As of the date of this announcement, in addition to imported products, three domestic companies have obtained drug approvals for other specifications of this product.